Zimmer price target raised to $113 from $105 at Cantor Cantor increased its price target on Zimmer after the company agreed to buy Biomet. The firm thinks that, beginning in the second year of the deal, Zimmer's accretion guidance could be slightly conservative. It keeps a Buy rating on the stock.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
Zimmer upgraded to Outperform from Market Perform at William Blair William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.